Aclaris Therapeutics (ACRS) announced that it has initiated a randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug in patients with moderate-to-severe atopic dermatitis. Top line results are expected in the second half of 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments
- Wedbush bullish on Aclaris Therapeutics, initiates with an Outperform
- Aclaris Therapeutics initiated with an Outperform at Wedbush
- Aclaris Therapeutics price target lowered to $16 from $20 at H.C. Wainwright
- Aclaris Therapeutics: Promising Pipeline and Strategic Developments Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue